PLRX
Pliant Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong sell
-59/100
Last price
1.03
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
1.03
Prev close
1.03
Day high
1.04
Day low
1.01
Volume
276.38K
Market cap
$63.78M
P/E (TTM)
—
52W range
1.01 – 1.95
Day trading desk
Gap from prior close
+0.00%
Prior close 1.03
VWAP
1.02
+0.60% from price
Relative volume
0.55×
Quiet session
Session range
2.97%
1.01 – 1.04
Position in range
67%
Mid range
ATR (14D)
0.04
3.80% of price
Prior day high
1.05
PDH
Prior day low
1.02
PDL
Bid / ask spread
—
Quote not published
Session volume
270.33K
Avg 488.36K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.63%
-6.6%
1M
-11.21%
-12.4%
3M
-9.65%
-14.2%
6M
-21.37%
-39.6%
YTD
-15.57%
-29.8%
1Y
-32.24%
-48.7%
3Y
-94.06%
-176.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on PLRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.38M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jan 20, 26 | COULIE BERNARD J Chief Executive Officer |
SELL | 89.38K | $114.40K | Direct |
| Jan 20, 26 | CUMMINGS KEITH LAMONT Chief Financial Officer |
SELL | 24.00K | $30.72K | Direct |
| Jan 20, 26 | CHEUNG LILY Officer |
SELL | 7.53K | $9.64K | Direct |
| Jan 20, 26 | KUO MINNIE Chief Operating Officer |
SELL | 6.92K | $8.85K | Direct |
| Jan 23, 25 | LEFEBVRE ERIC Officer |
STOCK | 45.65K | $0 | Direct |
| Jan 23, 25 | HULL JOHANNES P. Officer |
STOCK | 40.15K | $0 | Direct |
| Jan 23, 25 | COULIE BERNARD J Chief Executive Officer |
STOCK | 162.50K | $0 | Direct |
| Jan 23, 25 | CUMMINGS KEITH LAMONT Chief Financial Officer |
STOCK | 56.65K | $0 | Direct |
| Jan 23, 25 | OUIMETTE MICHAEL General Counsel |
STOCK | 35.00K | $0 | Direct |
| Jan 23, 25 | CHEUNG LILY Officer |
STOCK | 25.88K | $0 | Direct |
| Jan 22, 25 | OUIMETTE MICHAEL General Counsel |
SELL | 23.50K | $261.10K | Direct |
| Jan 17, 25 | LEFEBVRE ERIC Officer |
SELL | 18.48K | $206.97K | Direct |
| Jan 17, 25 | HULL JOHANNES P. Officer |
SELL | 15.94K | $178.50K | Direct |
| Jan 17, 25 | COULIE BERNARD J Chief Executive Officer |
SELL | 52.42K | $587.15K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHEUNG LILY |
Officer | 44.85K | Sale |
COULIE BERNARD J |
Chief Executive Officer | 914.92K | Sale |
CUMMINGS KEITH LAMONT |
Chief Financial Officer | 297.21K | Sale |
HULL JOHANNES P. |
Officer | 283.50K | Stock Award(Grant) |
KUO MINNIE |
Chief Operating Officer | 37.81K | Sale |
LEFEBVRE ERIC |
Officer | 240.22K | Stock Award(Grant) |
OUIMETTE MICHAEL |
General Counsel | 105.54K | Stock Award(Grant) |
Fundamentals
Market cap$63.78M
Enterprise value$-65.58M
Revenue (TTM)—
Gross profit—
EBITDA$-89.87M
Net income$-92.29M
EPS (TTM)$-1.50
Free cash flow$-42.51M
Total cash$158.10M
Total debt$28.74M
Book value / share$2.37
Shares outstanding61.92M
Float55.03M
Short % of float6.10%
Dividend yield0.00%
Beta (5Y)1.28
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.80
PEG ratio—
Price / sales—
Price / book0.43
EV / revenue—
EV / EBITDA0.73
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-50.29%
Return on assets-23.27%
Debt / equity19.56
Current ratio9.90
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $1.58M | $9.69M | — |
| Operating revenue | $0 | $0 | $1.58M | $9.69M | — |
| Research & development | $109.16M | $169.31M | $127.80M | $96.94M | -35.5% |
| Selling, general & admin | $47.22M | $59.05M | $57.93M | $39.95M | -20.0% |
| Total operating expense | $156.37M | $228.37M | $185.72M | $136.88M | -31.5% |
| Operating income | -$156.37M | -$228.37M | -$184.15M | -$127.20M | +31.5% |
| Net interest income | $8.86M | $18.06M | $22.81M | $3.88M | -51.0% |
| Pre-tax income | -$149.34M | -$210.30M | -$161.34M | -$123.32M | +29.0% |
| Net income | -$149.34M | -$210.30M | -$161.34M | -$123.32M | +29.0% |
| Net income to common | -$149.34M | -$210.30M | -$161.34M | -$123.32M | +29.0% |
| Basic EPS | -2.43 | -3.47 | -2.75 | -2.94 | +30.0% |
| Diluted EPS | -2.43 | -3.47 | -2.75 | -2.94 | +30.0% |
| EBIT | -$146.78M | -$207.28M | -$160.07M | -$122.53M | +29.2% |
| EBITDA | -$145.09M | -$205.16M | -$158.23M | -$120.71M | +29.3% |
| Basic shares | 61.37M | 60.54M | 58.72M | 42.02M | +1.4% |
| Diluted shares | 61.37M | 60.54M | 58.72M | 42.02M | +1.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.45M | $71.19M | $63.23M | $33.69M | — | -36.2% |
| Cash & short-term investments | $190.94M | $355.72M | $494.25M | $331.19M | — | -46.3% |
| Accounts receivable | — | — | $0 | $1.98M | $2.00M | — |
| Total current assets | $196.45M | $362.26M | $505.50M | $340.31M | — | -45.8% |
| Property, plant & equipment | $26.91M | $32.77M | $4.78M | $9.91M | — | -17.9% |
| Total assets | $225.23M | $396.95M | $512.15M | $350.61M | — | -43.3% |
| Total current liabilities | $16.36M | $33.22M | $28.52M | $23.91M | — | -50.7% |
| Long-term debt | — | $30.21M | $10.05M | $9.93M | — | — |
| Total debt | $29.11M | $60.19M | $11.37M | $15.81M | — | -51.6% |
| Total liabilities | $44.02M | $92.87M | $38.58M | $37.27M | — | -52.6% |
| Retained earnings | -$859.40M | -$710.05M | -$499.75M | -$338.41M | — | -21.0% |
| Shareholder equity | $181.21M | $304.08M | $473.58M | $313.34M | — | -40.4% |
| Working capital | $180.08M | $329.05M | $476.98M | $316.40M | — | -45.3% |
| Net tangible assets | $181.21M | $304.08M | $473.58M | $313.34M | — | -40.4% |
| Shares issued | 61.45M | 60.86M | 59.92M | 48.94M | — | +1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$149.34M | -$210.30M | -$161.34M | -$123.32M | +29.0% |
| Depreciation & amortisation | $1.70M | $2.13M | $1.84M | $1.82M | -20.2% |
| Stock-based compensation | $26.23M | $37.63M | $44.48M | $22.60M | -30.3% |
| Change in working capital | -$15.94M | $9.09M | $1.25M | $4.22M | -275.4% |
| Operating cash flow | -$128.34M | -$155.50M | -$116.36M | -$94.63M | +17.5% |
| Capital expenditure | -$374.00K | -$3.85M | -$921.00K | -$1.76M | +90.3% |
| Investing cash flow | $134.29M | $140.34M | -$127.01M | -$150.20M | -4.3% |
| Financing cash flow | -$31.70M | $23.12M | $274.40M | $226.85M | -237.1% |
| Free cash flow | -$128.71M | -$159.35M | -$117.28M | -$96.39M | +19.2% |
| End cash position | $46.93M | $72.67M | $64.72M | $33.68M | -35.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $16.73M | $13.58M | $15.59M | $17.94M | $32.20M | +23.1% |
| Selling, general & admin | $7.13M | $8.19M | $7.99M | $10.33M | $13.39M | -12.9% |
| Total operating expense | $23.86M | $21.77M | $23.58M | $28.27M | $45.59M | +9.6% |
| Operating income | -$23.86M | -$21.77M | -$23.58M | -$28.27M | -$45.59M | -9.6% |
| Net interest income | $1.49M | $1.73M | $1.83M | $1.97M | $2.29M | -13.9% |
| Pre-tax income | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | -11.6% |
| Net income | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | -11.6% |
| Net income to common | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | -11.6% |
| Basic EPS | -0.36 | -0.32 | -0.38 | -0.43 | -0.71 | -12.5% |
| Diluted EPS | -0.36 | -0.32 | -0.38 | -0.43 | -0.71 | -12.5% |
| EBIT | -$22.37M | -$20.04M | -$23.44M | -$25.49M | -$42.49M | -11.6% |
| EBITDA | -$22.12M | -$19.78M | -$23.08M | -$25.05M | -$42.04M | -11.9% |
| Basic shares | 61.92M | 61.80M | 61.45M | 61.41M | 61.39M | +0.2% |
| Diluted shares | 61.92M | 61.80M | 61.45M | 61.41M | 61.39M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.88M | $22.19M | $45.45M | $93.73M | $86.82M | — | +12.1% |
| Cash & short-term investments | $158.10M | $170.89M | $190.94M | $241.80M | $262.87M | — | -7.5% |
| Total current assets | $163.14M | $174.93M | $196.45M | $245.59M | $267.44M | — | -6.7% |
| Property, plant & equipment | $24.70M | $25.80M | $26.91M | $29.14M | $30.51M | — | -4.2% |
| Total assets | $189.88M | $202.60M | $225.23M | $276.60M | $299.82M | — | -6.3% |
| Total current liabilities | $16.48M | $10.36M | $16.36M | $17.62M | $20.59M | — | +59.1% |
| Long-term debt | — | — | — | $30.44M | $30.36M | $30.28M | — |
| Total debt | $28.74M | $28.78M | $29.11M | $59.86M | $60.38M | — | -0.1% |
| Total liabilities | $42.95M | $37.43M | $44.02M | $76.29M | $79.74M | — | +14.8% |
| Retained earnings | -$901.81M | -$879.44M | -$859.40M | -$835.82M | -$809.52M | — | -2.5% |
| Shareholder equity | $146.93M | $165.17M | $181.21M | $200.31M | $220.08M | — | -11.0% |
| Working capital | $146.66M | $164.57M | $180.08M | $227.96M | $246.85M | — | -10.9% |
| Net tangible assets | $146.93M | $165.17M | $181.21M | $200.31M | $220.08M | — | -11.0% |
| Shares issued | 61.92M | 61.91M | 61.45M | 61.45M | 61.39M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$22.37M | -$20.04M | -$23.58M | -$26.30M | -$43.30M | — | -11.6% |
| Depreciation & amortisation | $249.00K | $264.00K | $365.00K | $436.00K | $447.00K | — | -5.7% |
| Stock-based compensation | $4.19M | $4.25M | $4.53M | $6.42M | $6.38M | — | -1.6% |
| Change in working capital | $4.41M | -$4.87M | -$2.04M | -$2.75M | -$6.92M | — | +190.7% |
| Operating cash flow | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.60M | — | +33.4% |
| Capital expenditure | — | — | — | — | -$112.00K | -$262.00K | — |
| Investing cash flow | $15.49M | -$4.10M | $1.77M | $27.92M | $35.49M | — | +477.8% |
| Financing cash flow | $0 | $74.00K | -$32.27M | $72.00K | $0 | — | -100.0% |
| Free cash flow | -$12.80M | -$19.23M | -$17.79M | -$21.08M | -$40.72M | — | +33.4% |
| End cash position | $26.36M | $23.67M | $46.93M | $95.21M | $88.30M | — | +11.4% |
Options analytics
Put / call volume
1.95
Put-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
0.50
-51.5% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
22
Contracts, this expiry
Put volume
43
Contracts, this expiry
Heaviest call OI
2.50
36 contracts
Heaviest put OI
0.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.34 | -0.36 | -4.4% |
| Mar 2026 | -0.36 | -0.32 | +10.6% |
| Dec 2025 | -0.38 | -0.35 | +6.5% |
| Sep 2025 | -0.52 | -0.43 | +18.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.37 | 3 | $0 | 0.0% |
| Next quarter | -0.37 | 3 | $0 | 0.0% |
| Current year | -1.43 | 3 | $0 | 0.0% |
| Next year | -1.28 | 3 | $0 | 0.0% |
Analyst targets & ownership
Mean target$2.00
High target$2.00
Low target$2.00
Implied upside94.17%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 0
Hold3
Sell / Strong sell0 / 1
Held by insiders2.23%
Held by institutions78.55%
Institutions holding110
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
1.07
-4.01% from price
SMA 20
1.10
-6.41% from price
SMA 50
1.10
-6.36% from price
SMA 100
1.13
-8.60% from price
SMA 200
1.19
-13.65% from price
EMA 12
1.07
-3.79% from price
EMA 26
1.09
-5.73% from price
EMA 50
1.11
-6.91% from price
RSI (14)
37.5
Neutral
MACD (12,26,9)
-0.02
Hist -0.01
ATR (14)
0.04
3.80% of price
Realised vol 30D
41.5%
Annualised
Bollinger upper
1.18
20, 2σ
Bollinger lower
1.02
20, 2σ
50 / 200 cross
Death
1.10 vs 1.19
Trend bias
Below 200
-13.65%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.01
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
41.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-44.9%
Peak to trough
Max drawdown 5Y
-97.2%
Peak to trough
ATR 14
0.04
3.80% of price
Beta (reported)
1.28
5Y monthly, from filing
Short interest
Shares short
3.69M
Prior 2.77M
Change vs prior
+33.4%
Shorts adding
% of float
6.10%
Normal
% of shares out
5.96%
Against total outstanding
Days to cover
8.4
Crowded exit
Float
55.03M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 13, 26 | Canaccord Genuity | MAINTAINED | Hold | Hold |
| Mar 12, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Nov 7, 25 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Oct 10, 25 | JP Morgan | DOWNGRADE | Neutral | Underweight |
| Aug 8, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 18, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Mar 4, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Mar 4, 25 | Citigroup | MAINTAINED | Neutral | Neutral |
| Mar 4, 25 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Mar 4, 25 | Wells Fargo | MAINTAINED | Equal-Weight | Equal-Weight |
| Mar 4, 25 | Needham | DOWNGRADE | Buy | Hold |
| Mar 3, 25 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-06-11
Periodic Financial Reports
10-Q · 2026-05-11
Proxy Statements
DEF 14A · 2026-04-22
Corporate Changes & Voting Matters
8-K · 2026-04-17
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-04-02
Offering Registrations
S-3 · 2026-03-30
Headlines
Pliant Therapeutics Appoints David Raben as Chief Medical Officer
MT Newswires · 6d ago
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
GlobeNewswire · 6d ago
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
GlobeNewswire · 50d ago
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · 56d ago
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
GlobeNewswire · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.